Treatment of cognitive dysfunction associated with Alzheimer's disease with cholinergic precursors. Ineffective treatments or inappropriate approaches?
- 1 November 2001
- journal article
- review article
- Published by Elsevier in Mechanisms of Ageing and Development
- Vol. 122 (16) , 2025-2040
- https://doi.org/10.1016/s0047-6374(01)00310-4
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- Rivastigmine for Alzheimer's diseasePublished by Wiley ,2000
- Tacrine for Alzheimer's diseaseCochrane Database of Systematic Reviews, 1999
- The regulation of amyloid precursor protein metabolism by cholinergic mechanisms and neurotrophin receptor signalingProgress in Neurobiology, 1998
- Effects of CDP-Choline Treatment on Neurobehavioral Deficits after TBI and on Hippocampal and Neocortical Acetlycholine ReleaseJournal of Neurotrauma, 1997
- Effects of CDP-Choline on acetylcholine-induced relaxation of the perfused carotid vascular beds of the ratGeneral Pharmacology: The Vascular System, 1994
- Pharmacological characterization of a novel muscarinic partial agonist, YM796, in transfected cells expressing the m1 or m2 muscarinic receptor geneLife Sciences, 1992
- The Cholinergic Hypothesis of Geriatric Memory DysfunctionScience, 1982
- Alzheimer's Disease and Senile Dementia: Loss of Neurons in the Basal ForebrainScience, 1982
- Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia.BMJ, 1978
- SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASEPublished by Elsevier ,1976